Axsome Therapeutics's three largest insider shareholders as of May 30, 2026 are Mark Coleman (Director, 403.86K shares), Mark Coleman (Director, 47.14K shares), Nick Pizzie (Chief Financial Officer, 42.59K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Mark E Saad | - | 10,002 | 0 | 02 Jan, 2026 |
| Mark Coleman | - | 0 | 403,856 | 15 Sep, 2023 |
| Nick Pizzie | Chief Financial Officer | 42,588 | 0 | 23 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 21 Apr, 2026 | Nick Pizzie | Performance Stock Units | A | 8,188 | $0.00 | 8,188 | D | A |
| 21 Apr, 2026 | Herriot Tabuteau | Performance Stock Units | A | 24,081 | $0.00 | 24,081 | D | A |
| 22 Apr, 2026 | Ari Maizel | Common Stock | A | 7,500 | $70.73 | 7,500 | D | M |
| 21 Apr, 2026 | Hunter R. Murdock | Performance Stock Units | A | 7,224 | $0.00 | 7,224 | D | A |
| 21 Apr, 2026 | Nick Pizzie | Performance Stock Units | A | 8,188 | $0.00 | 8,188 | D | A |
| 21 Apr, 2026 | Mark L. Jacobson | Performance Stock Units | A | 8,669 | $0.00 | 8,669 | D | A |
| 22 Apr, 2026 | Ari Maizel | Common Stock | D | 7,500 | $182.42 | 0 | D | S |
| 22 Apr, 2026 | Ari Maizel | Stock Option (Right to Buy) | D | 7,500 | $0.00 | 23,710 | D | M |
| 26 Feb, 2026 | Nick Pizzie | Restricted Stock Units | A | 18,570 | $0.00 | 18,570 | D | A |
| 26 Feb, 2026 | Nick Pizzie | Restricted Stock Units | A | 18,570 | $0.00 | 18,570 | D | A |
| 26 Feb, 2026 | Mark Coleman | Common Stock | D | 25,000 | $161.11 | 47,140 | D | S |
| 26 Feb, 2026 | Mark Coleman | Common Stock | D | 25,000 | $161.11 | 47,140 | D | S |
| 26 Feb, 2026 | Nick Pizzie | Restricted Stock Units | A | 18,570 | $0.00 | 18,570 | D | A |
| 26 Feb, 2026 | Mark Coleman | Common Stock | D | 25,000 | $161.11 | 47,140 | D | S |
| 23 Feb, 2026 | Mark Coleman | Common Stock | A | 6,250 | $4.95 | 72,140 | D | M |
| 23 Feb, 2026 | Mark Coleman | Common Stock | A | 6,250 | $4.95 | 72,140 | D | M |
| 23 Feb, 2026 | Mark Coleman | Common Stock | A | 6,250 | $4.95 | 72,140 | D | M |
| 23 Feb, 2026 | Mark Coleman | Stock Option (Right to Buy) | D | 6,250 | $0.00 | 7,721 | D | M |
| 23 Feb, 2026 | Mark Coleman | Stock Option (Right to Buy) | D | 6,250 | $0.00 | 7,721 | D | M |
| 23 Feb, 2026 | Mark Coleman | Stock Option (Right to Buy) | D | 6,250 | $0.00 | 7,721 | D | M |